NOS2 and chronic obstructive pulmonary disease: The beneficial effects (see Figure 3) of suppressing iNOS activity by pharmacological inhibition (Table 3) or genetic depletion (Table 4) were disclosed across a variety of animal models of PH and PH-associated diseases, such as COPD or IPF.